Latest News

Ocrelizumab Subcut Receives Medsafe Registration as Pressure Mounts to Fund Wider Range of MS Treatment Options

April 24, 2025 | Advocacy, Life with MS, News, Treatments

Photo by Kristine Wook, Unsplash. Medsafe have approved the registration of Ocrevus ® Subcutaneous (SC) (ocrelizumab and hyaluronidase) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The announcement on […]


Press Release: Pharmac Funding Stalemate for “Life-Changing” Multiple Sclerosis Drugs

March 27, 2025 | Advocacy, Media, News, Press Release, Treatments

There are calls for Pharmac to “quit stalling” and fund four affordable treatments to significantly improve quality of life for patients with Multiple Sclerosis (MS) in New Zealand – treatments which would also significantly reduce demand on New Zealand’s stretched […]


Update: Siponimod (Mayzent) for Secondary Progressive MS

November 16, 2022 | Advocacy, Funding, Treatments

At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]


Do you qualify for antiviral medication?

June 8, 2022 | Covid-19, Treatments

If you have tested positive for COVID-19 and your symptoms started in the past 5 days and you are on Fingolimod or Ocrelizumab for your MS, you may be eligible for antiviral medication to treat COVID-19. Your GP can prescribe […]